Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
phipa2
- Development stage
- Preclinical
- Lead developer
- Fudan University
01
Overview
phipa2 (also known as Pseudomonas phage phipa2) is a lytic bacteriophage belonging to the family Autographiviridae (specifically the genus Phikmvvirus) that specifically targets and lyses Pseudomonas aeruginosa. It was isolated from sewage samples at Zhongshan Hospital, Fudan University, Shanghai, China. phipa2 infects P. aeruginosa by binding to type IV pili (T4P) as its primary receptor, which is essential for bacterial twitching motility and biofilm formation. It is being investigated in preclinical research for its potential application in phage therapy to treat multidrug-resistant (MDR) Pseudomonas aeruginosa infections, particularly in the context of cystic fibrosis and other chronic infections.
- Other names
- Pseudomonas phage phipa2
02
Targets
PilA (Type IV pilus protein PilA)
Beyond the preview
Go deeper on phipa2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on phipa2.